Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.00
Bid: 38.00
Ask: 38.50
Change: 0.85 (2.29%)
Spread: 0.50 (1.316%)
Open: 37.95
High: 38.05
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Futura Regains Ownership of CSD500

28 Aug 2012 07:00

RNS Number : 7968K
Futura Medical PLC
28 August 2012
 



For immediate release

28 August 2012

 

 

Futura Medical plc

("Futura" or "the Company")

Futura Regains Ownership of CSD500

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that Futura and Reckitt Benckiser have been unable to reach a common ground acceptable to both parties in respect of their continued development and commercialisation of the CSD500 condom leading to a mutual agreement to terminate their commercial relationship.

Futura intends to partner CSD500 with one or more of the world's other leading condom or healthcare companies. Futura has received considerable interest from such companies and formal discussions will now commence.

In order to get CSD500 to market as quickly as possible Futura will take control of the manufacturing of the product and apply directly for a CE Mark. Manufacturing will be outsourced to a third party manufacturer for onward supply of finished condoms to commercial partners. To this end, development work with an independent contract condom manufacturer has already commenced. The manufacturer already has the necessary ISO 13485 certification for the manufacture of condoms with ancillary medicinal substances. 

Futura has ownership rights over all previous clinical data generated for the original approved dossier and therefore does not anticipate the need for any new clinical data. Futura expects to submit a new CE Mark dossier in the first half of 2013 to the regulatory authorities that approved CSD500 last year.

Futura has also regained worldwide ownership of MED2002, the Company's topical gel for the treatment of erectile dysfunction, which was also licensed to Reckitt Benckiser.

James Barder, Futura's Chief Executive, commented: "Futura has received considerable interest in CSD500 from potential marketing partners. We are therefore confident of relicensing the product on attractive commercial terms and of creating significant value for shareholders."

 

For any further information please contact:

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

Nomura Code Securities Limited

 

Phil Walker / Giles Balleny

Tel:+44 (0)20 7776 1200

 

 

 

For media enquiries please contact:

 

 

 

Buchanan

 

Mark Court / Fiona Henson / Sophie Cowles

Tel: +44 (0)20 7466 5000

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKQDKABKDNFB
Date   Source Headline
25th Jun 20212:55 pmRNSTR1: Notification of Major Holdings
15th Jun 20213:48 pmRNSTR-1: Notification of major holdings
9th Jun 20213:58 pmRNSTR-1: Notification of major holdings
3rd Jun 20214:19 pmRNSTR-1: Notification of major holdings
3rd Jun 202111:00 amRNSNotice of AGM and Annual Report
2nd Jun 202112:50 pmRNSResult of General Meeting & Total Voting Rights
1st Jun 20217:00 amRNSBlock Listing Six Monthly Return
17th May 20213:08 pmRNSPosting of Circular and Notice of General Meeting
17th May 20217:00 amRNSResult of Placing and Retail Offer
14th May 20214:41 pmRNSSecond Price Monitoring Extn
14th May 20214:35 pmRNSPrice Monitoring Extension
14th May 20214:31 pmRNSRetail Offer by PrimaryBid
14th May 20214:30 pmRNSProposed Placing to raise £10 mil & Retail Offer
4th May 20215:18 pmRNSTR-1: Notification of major holdings
4th May 20215:15 pmRNSTR-1: Notification of major holdings
4th May 20217:00 amRNSTotal Voting Rights
30th Apr 20217:00 amRNSFutura Receives Approval from EU Notified Body
28th Apr 20212:57 pmRNSTR-1: Notification of major holdings
28th Apr 20219:31 amRNSTR-1: Notification of major holdings
22nd Apr 20214:58 pmRNSTR-1: Notification of major holdings
19th Apr 20214:03 pmRNSCorrection – Conversion of Convertible Loan Notes
15th Apr 20212:42 pmRNSConversion of Convertible Loan Notes
14th Apr 20213:40 pmRNSRemuneration of Non-Executive Directors and TVR
14th Apr 20217:00 amRNSFull Year Results for the year ended 31 Dec 2020
1st Apr 20214:20 pmRNSExercise of Warrants, Issue of Equity & TVR
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.